Results 331 to 340 of about 1,334,419 (369)
Some of the next articles are maybe not open access.
Interleukin-2 (IL-2) and its receptor
Medical Oncology and Tumor Pharmacotherapy, 1986The interleukin-2 (IL-2) receptor system which is responsible for T-cell cycle progression is a unique hormone-receptor system in that both the ligand and the receptor need to be induced. In the present article I will review the biological and molecular characteristics of IL-2 and its receptor, as well as the differential triggering and growth ...
openaire +2 more sources
Cloning and sequence of guinea pig interleukin 2 (IL-2)
Archives of Toxicology, 1998Interleukin 2 (IL-2) is a T-cell proliferation factor released from TH0- and TH1-type helper T-cells and is an essential cytokine for certain immune responses. We reported here cloning and sequence of IL-2 cDNA in guinea pigs, which have been used for a long time in various immunological experiments and in vivo screening tests for skin sensitization ...
M, Takeyoshi, H, Iwata, T, Inoue
openaire +2 more sources
Receptors for Interleukin-2 (IL-2)
1995Abstract The a chain (p55, Tac) of the human IL-2 receptor, encoded by a single gene on chromosome 10, p14--15 (Leonard et al. 1985a), is produced as a 272 amino acid (aa) precursor with a 21 aa signal sequence (GenBank accession number K63122) (Leonard et al. 1985b).
S D Voss, R J Robb
openaire +1 more source
1995
Abstract IL-2 is a 15.5 kDa glycoprotein secreted primarily by activated T lymphocytes. The mature human IL-2 protein contains 133 amino acid residues, while the homologous proteins in other species contain 133 to 149 amino acids. The IL-2 primary translation product undergoes several post-translational processing steps that include ...
openaire +1 more source
Abstract IL-2 is a 15.5 kDa glycoprotein secreted primarily by activated T lymphocytes. The mature human IL-2 protein contains 133 amino acid residues, while the homologous proteins in other species contain 133 to 149 amino acids. The IL-2 primary translation product undergoes several post-translational processing steps that include ...
openaire +1 more source
β-Endorphin enhances interleukin-2 (IL-2) production in murine lymphocytes
Journal of Neuroimmunology, 1988Beta-endorphin has been reported to enhance T lymphocyte proliferation and cytolytic activity. In this report, it is demonstrated that beta-endorphin enhances the production of the T cell lymphokine, interleukin-2, from mitogen-stimulated, unfractionated murine splenocytes, as well from a cloned T cell line. The enhancement is naloxone irreversible and
W, Gilmore, L P, Weiner
openaire +2 more sources
Journal of Clinical Immunology, 1986
Approximately 65% (11/17) of cancer patients participating in an ongoing Phase I clinical trial with recombinant interleukin-2 developed nonneutralizing serum IgG anti-interleukin-2 antibodies within 1 month of initiating therapy. These antibodies could be detected using any of several standard techniques including immunoblots and enzyme-linked ...
M, Allegretta +7 more
openaire +2 more sources
Approximately 65% (11/17) of cancer patients participating in an ongoing Phase I clinical trial with recombinant interleukin-2 developed nonneutralizing serum IgG anti-interleukin-2 antibodies within 1 month of initiating therapy. These antibodies could be detected using any of several standard techniques including immunoblots and enzyme-linked ...
M, Allegretta +7 more
openaire +2 more sources
Interleukin-2 (IL-2) immunotherapy.
Medical laboratory sciences, 1990Various forms of immunotherapy have been employed for the treatment of cancer patients during the past 5 years, with recombinant interleukin-2 (IL-2) having been widely used in these treatment regimes. The progress of IL-2 immunotherapy is discussed.
M G, Macey, D H, Johnston
openaire +1 more source
Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration
Cancer Treatment Reviews, 1999There has been an apparent discrepancy between the results obtained with IL-2 based immunotherapy in animal tumour models, including veterinary cancer patients, and human cancer patients. We argue that this is due to differences in the therapeutic regimens used to treat human and veterinary cancer patients. The main differences are systemic therapy and
Bernsen, M.R. +4 more
openaire +3 more sources
Immunological Mechanisms of Interleukin-2 (IL-2) Treatment in HIV/AIDS Disease
Current Molecular Pharmacology, 2009HIV establishes a chronic infection that is marked by the progressive depletion of CD4+ T-cells, yet the mechanisms by which this depletion arises are a matter of controversy. Evidence is accumulating that T CD4+ depletion is not effected solely by virus-mediated killing and that mechanisms involving T-cell dynamics play a major role in the ...
C. Tincati +2 more
openaire +3 more sources
Gan to kagaku ryoho. Cancer & chemotherapy, 1994
Interleukin-2, a polypeptide lymphokine that induces proliferation of antigen- or mitogen-stimulated T cells, was first described as "T-cell growth factor" by Morgan et al. in 1976. IL-2 is one of several lymphocyte-produced messenger regulatory molecules that modulate immunocyte function. The main secretory source of IL-2 is the T-helper cell. In 1983,
openaire +1 more source
Interleukin-2, a polypeptide lymphokine that induces proliferation of antigen- or mitogen-stimulated T cells, was first described as "T-cell growth factor" by Morgan et al. in 1976. IL-2 is one of several lymphocyte-produced messenger regulatory molecules that modulate immunocyte function. The main secretory source of IL-2 is the T-helper cell. In 1983,
openaire +1 more source